AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03036319 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitively based intervention
Description: Participants may receive a cognitively based intervention that targets the particular cognitive and/or functional abilities of interest. This includes methods of cognitive training, cognitive remediation, and cognitive rehabilitation for up to 260 sessions
Study NCT02890199 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Study NCT03715829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600
Description: Maintenance Dose B. Oral tablet taken QD
Study NCT03715829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600
Description: Maintenance Dose C. Oral tablet taken QD
Study NCT03715829 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT03715829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF06700841
Description: Oral tablet taken QD
Study NCT03715829 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: narrow-band UVB phototherapy
Description: Phototherapy will be combined with PF-06651600
Study NCT03036319 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tACS
Description: Participants will receive active transcranial alternating current stimulation at up to 4mA per electrode for up to 40 minutes for up to 260 sessions
Study NCT00764426 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: red wine, beer, ethanol
Description: Alcoholic beverages equivalent to 30g of alcohol per day for men and 20g/d for women for 3 weeks
Study NCT03036319 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham tACS
Description: Participants will receive sham transcranial alternating current stimulation for up to 260 sessions
Study NCT00860340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: 100 mg tablet of Spironolactone (Aldactone) by mouth with half a glass of water.
Study NCT03036319 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham tACS
Description: Participants will receive sham transcranial alternating current stimulation for up to 260 sessions
Study NCT03036319 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tRNS
Description: Participants will receive active transcranial random noise stimulation at up to 4mA per electrode for up to 40 minutes for up to 260 sessions
Study NCT00764426 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: de-alcoholised red wine, de-alcoholised beer, water
Description: de-alcoholised red wine, de-alcoholised beer, water
Study NCT03036319 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham tRNS
Description: Participants will receive sham transcranial random noise stimulation for up to 260 sessions
Study NCT04634136 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Lab tests
Description: CBC and differential counts, blood electrolytes, magnesium, calcium, phosphorus, urea \& creatinine, liver enzymes (AST, ALT, gGT)
Study NCT04634136 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Lab tests
Description: CBC and differential counts, blood electrolytes, magnesium, calcium, phosphorus, urea \& creatinine, liver enzymes (AST, ALT, gGT)
Study NCT03036319 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham tRNS
Description: Participants will receive sham transcranial random noise stimulation for up to 260 sessions
Study NCT02211859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 2536
Study NCT04634136 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: ECG
Description: Electrocardiogram
Study NCT04634136 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: ECG
Description: Electrocardiogram
Study NCT01187199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Starting dose 12.5 mg by vein given on day 1, 8, and 15 of a 21 day cycle.
Study NCT01187199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Starting dose 5 mg/kg given by vein on day 1 of a 21 day cycle.
Study NCT03015740 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT04634136 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cannabinoid Levels
Description: Determination of levels of cannabidiol (CBD) and delta-9-tetrahydrocannbinol (THC) for determination of levels at following time(s) after ingestion: 0, 1, 2, 4, 8 and 24 hours.
Study NCT04634136 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Full-spectrum Medical Canabis Product (HemPhar)
Description: Active substance
Study NCT04634136 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04634136 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Spasticity level according to modified Ashworth scale (Bohannon)
Description: A trained physiotherapist will assess spasticity level according to modified Ashworth scale (Bohannon), which is 6-level scale for assessment of spasticity.~Modified Ashworth/Bohannon Scoring Scale (Bohannon and Smith, 1987):~0 No increase in muscle tone~1. Slight increase in muscle tone, manifested by a catch and release or by minimal resistance at the end of the range of motion when the affected part(s) is moved in flexion or extension 1+ Slight increase in muscle tone, manifested by a catch, followed by minimal resistance throughout the remainder (less than half) of the range of movement (ROM )~2. More marked increase in muscle tone through most of the ROM, but affected part(s) easily moved~3. Considerable increase in muscle tone, passive movement difficult~4. Affected part(s) rigid in flexion or extension~Best score is 0 (no spasticity), worst score is 4 (severe spasticity).
Study NCT04634136 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Spasticity level according to modified Ashworth scale (Bohannon)
Description: A trained physiotherapist will assess spasticity level according to modified Ashworth scale (Bohannon), which is 6-level scale for assessment of spasticity.~Modified Ashworth/Bohannon Scoring Scale (Bohannon and Smith, 1987):~0 No increase in muscle tone~1. Slight increase in muscle tone, manifested by a catch and release or by minimal resistance at the end of the range of motion when the affected part(s) is moved in flexion or extension 1+ Slight increase in muscle tone, manifested by a catch, followed by minimal resistance throughout the remainder (less than half) of the range of movement (ROM )~2. More marked increase in muscle tone through most of the ROM, but affected part(s) easily moved~3. Considerable increase in muscle tone, passive movement difficult~4. Affected part(s) rigid in flexion or extension~Best score is 0 (no spasticity), worst score is 4 (severe spasticity).
Study NCT04634136 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Gross Motor Function Measure
Description: A trained physiotherapist will assess Gross Motor Function Measure (GMFM-88) which is commonly used in the evaluation of gross motor function in children with cerebral palsy~The Gross Motor Function Measure-88 (GMFM-88) is a standardized observational instrument developed to measure change in gross motor function over time. The test consists of 88 items categorized in five dimensions (Dimension A: lying and rolling, Dimension B: sitting, Dimension C: crawling and kneeling, Dimension D: standing and Dimension E: walking, running and jumping). The test was conducted as described in the GMFM-88 manual . A percentage score as compared to maximum is calculated for each dimension and for the total score of the five dimensions.~Reference curves exist for GMFM-88 for each age group.~Floor score is 4 (minimum score / worst), ceiling score (maximum score / best) is 75.
Study NCT04634136 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Gross Motor Function Measure
Description: A trained physiotherapist will assess Gross Motor Function Measure (GMFM-88) which is commonly used in the evaluation of gross motor function in children with cerebral palsy~The Gross Motor Function Measure-88 (GMFM-88) is a standardized observational instrument developed to measure change in gross motor function over time. The test consists of 88 items categorized in five dimensions (Dimension A: lying and rolling, Dimension B: sitting, Dimension C: crawling and kneeling, Dimension D: standing and Dimension E: walking, running and jumping). The test was conducted as described in the GMFM-88 manual . A percentage score as compared to maximum is calculated for each dimension and for the total score of the five dimensions.~Reference curves exist for GMFM-88 for each age group.~Floor score is 4 (minimum score / worst), ceiling score (maximum score / best) is 75.
Study NCT04634136 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Borg rating of perceived exertion scale
Description: Borg rating of perceived exertion scale
Study NCT04634136 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Borg rating of perceived exertion scale
Description: Borg rating of perceived exertion scale
Study NCT04634136 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Edmonton symptom assessment system
Description: Edmonton symptom assessment system and general impression scale (1 - very much improved; 7 - very much worse).
Study NCT01187199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Starting dose 30 mg/m2 given by vein on day 1 of a 21 day cycle.
Study NCT04634136 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Edmonton symptom assessment system
Description: Edmonton symptom assessment system and general impression scale (1 - very much improved; 7 - very much worse).
Study NCT03015740 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT03015740 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03015740 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03015740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitravatinib
Description: Given PO
Study NCT01187199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Starting dose 200 mg by mouth daily for a 21 day cycle.
Study NCT01187199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Starting dose AUC 2 by vein on day 1 of a 21 day cycle.
Study NCT03805646 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Phone-based Triage Tool
Description: The proposed intervention is a mobile phone-administered survey. Participants that have been admitted to participating hospitals for treatment of injury will be contacted by mobile phone approximately two weeks after discharge. A seven-question survey will be administered over the phone to each participant. Cross-validation with a separately administered in-person physical exam will be performed to assess the survey tool's prediction of who needs further care for treatment of their injury.
Study NCT02016872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FMISO
Study NCT02016872 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PET/CT
Study NCT00798265 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gardasil
Description: .5 mL dose injected intramuscular (IM) at 0, 2 and 6 months
Study NCT00798265 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Gardasil
Description: .5 mL dose injected intramuscular (IM) at 0, 2 and 6 months
Study NCT00798265 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Survey
Description: Administration of online risk behavior and knowledge survey done at week 0.
Study NCT00798265 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Survey
Description: Administration of online risk behavior and knowledge survey done at week 0.
Study NCT04207255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opaganib
Description: 500mg of Opaganib orally twice a day continuously.
Study NCT04207255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: IV as directed by SOC
Study NCT04207255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: IV as directed by SOC
Study NCT04207255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opaganib
Description: 250mg of Opaganib orally twice a day continuously.
Study NCT03116022 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estriol
Description: Women using drug 1 mg / 1g in the proximal third of the vagina every other night for 12 weeks
Study NCT00616096 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: immunoadsorption
Description: First cycle: week 1, day 1-5~Second cycle: week 5, day 1-5
Study NCT02476331 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Working memory training
Description: The neurocognitive training program will be provided by an online platform called BrainGymmer (https://www.braingymmer.com/en/brain-games/). The experimental group will complete the working memory training, which involves three games: N-back, Multi-Memory, and Moving Memory. These games are designed to engage processes involving updating and manipulation of information. All of the training games provided by BrainGymmer are adaptive, meaning that the level of difficulty increases as users develop expertise on a given task. Participants randomized to the cognitive training arm will complete the training games for 30 minutes per day, 5 days a week, for a total of 10 weeks.
Study NCT00812318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1265744 10 mg oral solution
Description: GSK1265744
Study NCT00812318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1265744 5 mg tablet
Description: GSK1265744 5mg tablet, fasted
Study NCT00812318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1265744 5 mg tablet
Description: GSK1265744 5mg tablet, fed
Study NCT02538211 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rotavirus vaccine, Tetanus vaccine and Pneumococcal vaccine
Description: All subjects will be given an oral dose of the rotavirus vaccine, RotarixTM, and intramuscular injections of the Tetanus vaccine and Pneumococcal vaccine, Pneumo 23.
Study NCT02538211 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Rotavirus vaccine, Tetanus vaccine and Pneumococcal vaccine
Description: All subjects will be given an oral dose of the rotavirus vaccine, RotarixTM, and intramuscular injections of the Tetanus vaccine and Pneumococcal vaccine, Pneumo 23.
Study NCT01415596 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: salbutamol
Study NCT01415596 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03088007 — intervention group
Intervention type: OTHER
Intervention: Cognitive, adaptive, behavioral and academic assessment
Description: Cognitive, adaptive, behavioral and academic assessment will be performed if not available in the records, using WISC-IV, VABS, GECEN and an academic skills rating form.
Study NCT01450800 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrofurantoin
Description: Nitrofurantoin 100mg po daily to be taken every day the patient uses a catheter for up to one week post-operatively
Study NCT03408314 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PediQUEST Response
Description: PediQUEST Response consists of regular feedback of electronic patient reported outcomes (child symptoms and quality of life) to providers and families coupled with involvement of the palliative care team, who will meet with families and providers within three weeks of randomization and follow-up at least monthly as deemed necessary based on PediQUEST feedback reports and other clinical indications.
Study NCT03408314 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Cancer Care
Description: Patients assigned to the usual cancer care arm, will receive the standard care provided by participating sites + be required to complete PediQUEST surveys (but no reports will be generated).
Study NCT03394612 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: EHSG-KF
Description: Transplantation of autologous dermo-epidermal skin substitute EHSG-KF to the experimental area
Study NCT03394612 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: STSG
Description: Transplantation of autologous split-thickness skin graft to the control area
Study NCT01999101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Px-104
Description: 28 days treatment
Study NCT04000230 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TCIT
Description: TCIT consists of the following:~* CDI Teach Session: Teachers will participate in two training workshops in Child-Directed Interaction (CDI) skills. Specifically, teachers will learn to use positive attention skills and active ignoring.~* CDI Coaching: Teachers will receive 90 minutes of CDI coaching in the classroom once or twice weekly for 6 total coaching sessions over a period of 4-6 weeks. The coach will observe the class and coach the teacher live using a microphone and bug-in-the-ear device.~* TDI Teach Session: Teachers will complete two training workshops in Teacher Directed Interaction (TDI) skills, which focus on increasing compliance and reducing disruptive behavior. Teachers will learn to present developmentally appropriate, direct, and clear instructions and consistent positive and negative consequences.~* TDI Coaching: Teachers will receive six 90-minute TDI coaching sessions once or twice weekly for 4-6 weeks.
Study NCT04000230 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TCIT
Description: TCIT consists of the following:~* CDI Teach Session: Teachers will participate in two training workshops in Child-Directed Interaction (CDI) skills. Specifically, teachers will learn to use positive attention skills and active ignoring.~* CDI Coaching: Teachers will receive 90 minutes of CDI coaching in the classroom once or twice weekly for 6 total coaching sessions over a period of 4-6 weeks. The coach will observe the class and coach the teacher live using a microphone and bug-in-the-ear device.~* TDI Teach Session: Teachers will complete two training workshops in Teacher Directed Interaction (TDI) skills, which focus on increasing compliance and reducing disruptive behavior. Teachers will learn to present developmentally appropriate, direct, and clear instructions and consistent positive and negative consequences.~* TDI Coaching: Teachers will receive six 90-minute TDI coaching sessions once or twice weekly for 4-6 weeks.
Study NCT04000230 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Booster
Description: Teachers in the Intervention group will receive additional booster sessions during the second half of the school year. Booster sessions consist of coaching teachers in CDI and TDI skills. Teachers receive 4-8 booster sessions.
Study NCT04593849 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ru-Yih-Jin- Huang-Saan(RYJHS), Wan-Yin-Gao-Jia-Jean-Wey(WYGJJW), placebo ( topical agent without therapeutic effects)
Description: We conduct a clinical trial using topical herbal medicine, including Ru-Yih-Jin- Huang-Saan(RYJHS) and Wan-Yin-Gao-Jia-Jean-Wey (WYGJJW) in treating post fracture pain and tissue swell. 24 eligible participants diagnosed of upper limb fracture with soft tissue injury grading of C1, C0 from Tscherne classification transferred from Orthopedic outpatient clinic and inpatient will be enrolled and randomly allocated to 4 groups, including experimental group A (RYJHS group), group B (WYGJJW group), placebo group( topical agent without therapeutic effects), and control group (only oral analgesics group), with 6 participants in each group.
Study NCT04593849 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ru-Yih-Jin- Huang-Saan(RYJHS), Wan-Yin-Gao-Jia-Jean-Wey(WYGJJW), placebo ( topical agent without therapeutic effects)
Description: We conduct a clinical trial using topical herbal medicine, including Ru-Yih-Jin- Huang-Saan(RYJHS) and Wan-Yin-Gao-Jia-Jean-Wey (WYGJJW) in treating post fracture pain and tissue swell. 24 eligible participants diagnosed of upper limb fracture with soft tissue injury grading of C1, C0 from Tscherne classification transferred from Orthopedic outpatient clinic and inpatient will be enrolled and randomly allocated to 4 groups, including experimental group A (RYJHS group), group B (WYGJJW group), placebo group( topical agent without therapeutic effects), and control group (only oral analgesics group), with 6 participants in each group.
Study NCT04593849 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ru-Yih-Jin- Huang-Saan(RYJHS), Wan-Yin-Gao-Jia-Jean-Wey(WYGJJW), placebo ( topical agent without therapeutic effects)
Description: We conduct a clinical trial using topical herbal medicine, including Ru-Yih-Jin- Huang-Saan(RYJHS) and Wan-Yin-Gao-Jia-Jean-Wey (WYGJJW) in treating post fracture pain and tissue swell. 24 eligible participants diagnosed of upper limb fracture with soft tissue injury grading of C1, C0 from Tscherne classification transferred from Orthopedic outpatient clinic and inpatient will be enrolled and randomly allocated to 4 groups, including experimental group A (RYJHS group), group B (WYGJJW group), placebo group( topical agent without therapeutic effects), and control group (only oral analgesics group), with 6 participants in each group.
Study NCT03904615 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey Protein
Description: 30 g of whey protein in flavored water, twice daily, during hospitalization and for 30 days post-discharge